Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) have earned a consensus rating of “Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $54.80.
A number of equities research analysts have commented on the stock. Lifesci Capital reissued an “outperform” rating on shares of Rocket Pharmaceuticals in a research report on Tuesday, December 26th. Needham & Company LLC reissued a “buy” rating and issued a $53.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, November 7th. StockNews.com raised shares of Rocket Pharmaceuticals to a “sell” rating in a research report on Friday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Wednesday, January 31st.
Insider Transactions at Rocket Pharmaceuticals
Institutional Trading of Rocket Pharmaceuticals
Hedge funds have recently made changes to their positions in the company. Capstone Investment Advisors LLC purchased a new position in Rocket Pharmaceuticals during the 4th quarter valued at about $217,000. TD Asset Management Inc increased its holdings in Rocket Pharmaceuticals by 38.2% during the 4th quarter. TD Asset Management Inc now owns 154,864 shares of the biotechnology company’s stock valued at $4,641,000 after acquiring an additional 42,834 shares in the last quarter. Franklin Resources Inc. increased its holdings in Rocket Pharmaceuticals by 60.8% during the 4th quarter. Franklin Resources Inc. now owns 1,072,910 shares of the biotechnology company’s stock valued at $32,155,000 after acquiring an additional 405,855 shares in the last quarter. Norges Bank purchased a new position in Rocket Pharmaceuticals during the 4th quarter valued at about $7,293,000. Finally, EFG Asset Management North America Corp. increased its holdings in Rocket Pharmaceuticals by 2.7% during the 4th quarter. EFG Asset Management North America Corp. now owns 155,205 shares of the biotechnology company’s stock valued at $4,645,000 after acquiring an additional 4,137 shares in the last quarter. Institutional investors and hedge funds own 94.49% of the company’s stock.
Rocket Pharmaceuticals Price Performance
Rocket Pharmaceuticals stock opened at $29.99 on Thursday. The firm has a market cap of $2.70 billion, a PE ratio of -9.31 and a beta of 1.11. Rocket Pharmaceuticals has a 52-week low of $14.89 and a 52-week high of $32.53. The company has a quick ratio of 13.35, a current ratio of 13.35 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $28.43 and its two-hundred day moving average is $22.19.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
- Five stocks we like better than Rocket Pharmaceuticals
- Why Consider Investing in Nanotechnology Stocks
- 3 attractive stocks that insiders are buying
- Manufacturing Stocks Investing
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Industrial Products Stocks Investing
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.